Neurofibromatosis Type 1 Revisited

被引:441
作者
Williams, Virginia C. [1 ,2 ]
Lucas, John [1 ,2 ]
Babcock, Michael A. [1 ,2 ]
Gutmann, David H. [3 ]
Korf, Bruce [4 ]
Maria, Bernard L. [1 ,2 ]
机构
[1] Med Univ S Carolina, Dept Pediat, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Neurosci, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA
[3] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[4] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA
关键词
neurofibromatosis type 1; neurofibroma; malignant peripheral nerve sheath tumor; neurofibromin; BONE-MINERAL DENSITY; NERVE SHEATH TUMORS; POSITRON-EMISSION-TOMOGRAPHY; PLEXIFORM NEUROFIBROMA; COGNITIVE DEFICITS; CLINICAL-FEATURES; NATURAL-HISTORY; MOUSE MODEL; FDG PET; PHASE-I;
D O I
10.1542/peds.2007-3204
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of similar to 1 per 2500 to 3000 individuals. Caused by a germ-line inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1. Moreover, improved understanding of how the neurofibromatosis type 1 protein, neurofibromin, regulates cell growth recently provided insight into the pathogenesis of the disease and has led to the development of new therapies. In this review, we describe the clinical manifestations, recent molecular and genetic findings, and current and developing therapies for managing clinical problems associated with neurofibromatosis type 1. Pediatrics 2009; 123: 124-133
引用
收藏
页码:124 / 133
页数:10
相关论文
共 83 条
[21]   Neurofibromatosis type 1 - Motor and cognitive function and T2-weighted MRI hyperintensities [J].
Feldmann, R ;
Denecke, J ;
Grenzebach, M ;
Schuierer, G ;
Weglage, J .
NEUROLOGY, 2003, 61 (12) :1725-1728
[22]   [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs):: a long-term clinical study [J].
Ferner, R. E. ;
Golding, J. F. ;
Smith, M. ;
Calonje, E. ;
Jan, W. ;
Sanjayanathan, V. ;
O'Doherty, M. .
ANNALS OF ONCOLOGY, 2008, 19 (02) :390-394
[23]   Neurofibromatous neuropathy in neurofibromatosis 1 (NF1) [J].
Ferner, RE ;
Hughes, RAC ;
Hall, SM ;
Upadhyaya, M ;
Johnson, MR .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (11) :837-841
[24]   Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 [J].
Ferner, Rosalie E. ;
Huson, Susan M. ;
Thomas, Nick ;
Moss, Celia ;
Willshaw, Harry ;
Evans, D. Gareth ;
Upadhyaya, Meena ;
Towers, Richard ;
Gleeson, Michael ;
Steiger, Christine ;
Kirby, Amanda .
JOURNAL OF MEDICAL GENETICS, 2007, 44 (02) :81-88
[25]   The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression [J].
Fisher, Michael J. ;
Basu, Sandip ;
Dombi, Eva ;
Yu, Jian Q. ;
Widemann, Brigitte C. ;
Pollock, Avrum N. ;
Cnaan, Avital ;
Zhuang, Hongming ;
Phillips, Peter C. ;
Alavi, Abass .
JOURNAL OF NEURO-ONCOLOGY, 2008, 87 (02) :165-171
[26]   Rapamycin causes regression of astrocytomas in tuberous sclerosis complex [J].
Franz, DN ;
Leonard, J ;
Tudor, C ;
Chuck, G ;
Care, M ;
Sethuraman, G ;
Dinopoulos, A ;
Thomas, G ;
Crone, KR .
ANNALS OF NEUROLOGY, 2006, 59 (03) :490-498
[27]  
Friedman J.M., 1999, Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, VThird, P29
[28]   Cardiovascular disease in neurofibromatosis 1: Report of the NF1 cardiovascular task force [J].
Friedman, JM ;
Arbiser, J ;
Epstein, JA ;
Gutmann, DH ;
Huot, SJ ;
Lin, AE ;
McManus, B ;
Korf, BR .
GENETICS IN MEDICINE, 2002, 4 (03) :105-111
[29]   Neurofibromatosis 1: Clinical manifestations and diagnostic criteria [J].
Friedman, JM .
JOURNAL OF CHILD NEUROLOGY, 2002, 17 (08) :548-554
[30]   Resection of small plexiform neurofibromas in neurofibromatosis type 1 children [J].
Friedrich R.E. ;
Schmelzle R. ;
Hartmann M. ;
Fünsterer C. ;
Mautner V.-F. .
World Journal of Surgical Oncology, 3 (1)